Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Tecnología de administración segura de medicamentos al colon

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOCH20181030001
Publicado:
12/11/2018
Caducidad:
13/11/2019
Resumen:
Científicos de una universidad suiza han desarrollado una tecnología de administración peroral de medicamentos al colon. La liberación del medicamento se retrasa hasta que alcanza el colon, evitando una administración prematura en el intestino delgado distal. La liberación completa del medicamento se lleva a cabo de forma rápida en el intestino grueso, garantizando una liberación colónica eficiente. La tecnología se basa en un carbohidrato polimérico con estado GRAS (Generalmente Reconocido como Seguro). La tecnología integra la respuesta a dos señales distintas para la liberación específica del medicamento en el colon: primero, el cambio del pH desde el estómago hasta el intestino delgado y, segundo, la presencia de un microbioma metabólicamente activo en el colon. Los desarrolladores buscan una compañía farmacéutica interesada en desarrollar y comercializar la tecnología. La cooperación se establecerá en el marco de un acuerdo de licencia o cooperación en materia de investigación.

Details

Tittle:
Technology for reliable drug targeting to the colon
Summary:
Scientists at a Swiss university developed a technology for colonic drug delivery by per-oral administration. The drug release is delayed until the colon is reached preventing premature release in the distal small intestine. Complete drug substance release takes place quickly in large intestinal environment assuring efficient colonic targeting. The developers seek a pharmaceutical company willing to develop and commercialize the technology. A license agreement or research cooperation is sought.
Description:
Efficient and reliable delivery of drugs to the colon has not been achieved so far, although urgently required for the treatment of inflammatory bowel disease, a malady with increasing incidence. The difficulty in consistent colonic delivery is caused by the individual and circumstantial variability of the human digestive tract (pH, residence time, water content, food intake, volume, peristaltic movement, etc.).

Scientists at a Swiss university of applied sciences have developed a novel technology for colonic drug delivery by per-oral administration.

To achieve colonic delivery coated tablets have been produced with a novel approach. The coating is a pH responsive polymer which dissolves after the gastric passage as soon as the small intestine is reached. Active pharmaceutical ingredient (API) release in the small intestine is prevented by a matrix composed of a polymeric carbohydrate. The matrix is not degraded by pancreatic enzymes and is stable in the small intestine. In contrast, rapid depolymerization of the matrix and API release take place in the large intestine triggered by catalytic activities of the microbiome in the colon.
The technology is based on a polymeric carbohydrate which has Generally Recognized as Safe (GRAS) status. The technology integrates response to two distinct signals for the specific drug release in the colon: Firstly, the pH change from stomach to small intestine and secondly the presence of a metabolically active microbiome in the colon.

Standard in vitro dissolution test carried out with tablets produced with the novel technology demonstrated that the release of the model drug 5-aminosalicylic acid (5-ASA) is delayed until the colon is reached, preventing premature release in the distal small intestine as often observed for commercially available products. Complete drug substance release took place quickly in large intestinal environment assuring efficient colonic targeting.

The developers now seek a pharmaceutical company willing to develop and commercialize the technology in the frame of a license agreement or research cooperation.

Advantages and Innovations:
Advantages and innovative aspects of the proposed technology are:
- reliable colonic delivery
- less premature release in small intestine compared to conventional tablets
- reduced systemic exposure resulting in reduced side effects
- improved therapeutic drug index
- smaller API dose possible due to improved drug utilization
- GRAS status of matrix
- low cost excipients
- tablets can be produced with standard production facilities

Stage of Development:
Prototype available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
IP solely owned by the university of applied sciences

Partner sought

Type and Role of Partner Sought:
The specific area of activity of the partner:
- Drug development organization, pharmaceutical company.

The tasks to be performed by the partner sought:
- Pre-clinical and clinical development of the drug delivery technology.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001016 Fisiología
03004007 Pharmaceutics
06001015 Productos farmacéuticos / medicamentos